An observational study in Sepsis, sponsored by Seoul National University Hospital. Recruiting at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by Seoul National University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Sepsis with a site in Korea, Republic of — 9 open to participants now, 9 under way, none of them phase 3. Sepsis · Korea, Republic of.
Among the 31 studies in Sepsis with a site in Korea, Republic of, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2014, is one of 11 observational ones, and was the 16th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →9 of the 31 studies in Sepsis with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+
Dohern Kym · Sites in Korea, Republic of
Ages 18+
Korea University Ansan Hospital · Sites in Korea, Republic of
Ages 19–80 · Healthy volunteers
Kangdong Sacred Heart Hospital · Sites in Korea, Republic of
Ages 18+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 16+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 6 · Phase 4 1
First in 2004; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 109 across the 20 interventional studies, 245 across the 11 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 31 have an industry lead sponsor. The 10 most frequent:
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 6 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
2 of the studies in Sepsis with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060560Dohern KymPresepsin Diagnostic Performance in Severe Burn Sepsis | 2026-12-31 |
| NCT07539883Seoul National University Bundang HospitalEffect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Sepsis with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to construct multi-center sepsis registry that can be used for data warehousing and clinical research.
This registry prospectively enrolls adult patients with severe sepsis or septic shock in 21 tertiary hospital emergency departments.
Registered data can be used for quality control and clinical research to reduce sepsis-related mortality.
Patients with severe sepsis or septic shock
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
any organ dysfunction as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
28-day mortality
According to hospital discharge record review and telephone follow-up.
Time frame: 28-day
90-day mortality
According to hospital discharge record review and telephone follow-up.
Time frame: 90-day
Organ support treatment (mechanical ventilation)
According to hospital record review
Time frame: hospital discharge (non-survivors) or 90 days (survivors)
Organ support treatment (renal replacement therapy)
According to hospital record review
Time frame: hospital discharge (non-survivors) or 90 days (survivors)
ICU length of stay
According to hospital record review
Time frame: hospital discharge (non-survivors) or 90 days (survivors)
Hospital length of stay
According to hospital record review
Time frame: hospital discharge (non-survivors) or 90 days (survivors)
The record gives a start of Aug 2014, a primary completion of Mar 2028 and a completion of Mar 2028. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →